Release Date: 12/06/13 14:03 Summary: Prospectus Delay and Cancellation of Shareholder Briefings Price Sensitive: No Download Document 56.2KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%